Sectors
ORKA
Oruka Therapeutics, Inc.
92.62
2 x 71.53
2 x 126.45
bid
ask
+
1.48
1.62%
2 @ 07:30 PM
92.62 +0.00 (0.00%)
| Ytd | 205.58% | |
| 1y | 525.81% |
86.00
day range
93.88
14.67
52 week range
115.52
| Open | 91.00 | Prev Close | 91.14 | Low | 86.00 | High | 93.88 | Mkt Cap | 6.13B |
| Vol | 1.29M | Avg Vol | 1.21M | EPS | -2.04 | P/E | N/A | Forward P/E | -32.69 |
| Beta | -0.34 | Short Ratio | 9.52 | Inst. Own | 116.51% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 94.34 | 200-d Avg | 56.59 | 1yr Est | 153.75 |
| Income Statement | |||
| Operating Expenses | 50.11M | ||
| Research and Development Expense | 43.26M | ||
| Selling, General and Administrative Expense | 6.85M | ||
| Operating Income | -50.11M | ||
| Net Income | -41.21M | ||
| Net Income Common Stock | -41.21M | ||
| Net Income Common Stock (USD) | -41.21M | ||
| Consolidated Income | -41.21M | ||
| Earnings per Basic Share | -0.55 | ||
| Earnings per Basic Share (USD) | -0.55 | ||
| Earnings per Diluted Share | -0.55 | ||
| Earning Before Interest & Taxes (EBIT) | -41.21M | ||
| Earning Before Interest & Taxes (USD) | -41.21M | ||
| Weighted Average Shares | 62.87M | ||
| Weighted Average Shares Diluted | 62.87M | ||
| Balance Sheet | |||
| Cash and Equivalents | 268.47M | ||
| Cash and Equivalents (USD) | 268.47M | ||
| Investments | 857.11M | ||
| Investments Current | 605.09M | ||
| Investments Non-Current | 252.02M | ||
| Current Assets | 884.56M | ||
| Property, Plant & Equipment Net | 2.69M | ||
| Total Assets | 1.14B | ||
| Debt Current | 669.00K | ||
| Total Debt | 2.55M | ||
| Current Liabilities | 22.97M | ||
| Debt Non-Current | 1.88M | ||
| Total Liabilities | 24.85M | ||
| Accumulated Retained Earnings (Deficit) | -262.18M | ||
| Accumulated Other Comprehensive Income | -1.70M | ||
| Shareholders Equity | 1.11B | ||
| Shareholders Equity (USD) | 1.11B | ||
| Assets Non-Current | 254.84M | ||
| Total Debt (USD) | 2.55M | ||
| Liabilities Non-Current | 1.88M | ||
| Trade and Non-Trade Payables | 7.95M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 192.00K | ||
| Net Cash Flow from Financing | 663.04M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 218.95M | ||
| Issuance (Purchase) of Equity Shares | 663.04M | ||
| Net Cash Flow from Investing | -410.95M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -410.95M | ||
| Net Cash Flow from Operations | -33.15M | ||
| Share Based Compensation | 7.28M | ||